Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 16/20 | 0.47 |
| ▸ | THRA | P10827 | 15/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.47 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.47 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.47 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.34 |
| ▸ | RORC | P51449 | 1/20 | 0.30 |
| ▸ | NPBWR1 | P48145 | 2/20 | 0.30 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24408072 | 0.91 | THRB (0.40) | THRBTHRACYP2C9UGT1A1ABCG2 | |
| SCHEMBL26514527 | 0.86 | THRB (0.63) | THRBTHRACYP2C9UGT1A1ABCG2 | |
| SCHEMBL29527206 | 0.83 | THRB (0.40) | THRBTHRACYP2C9UGT1A1ABCG2 | |
| SCHEMBL24408104 | 0.83 | THRB (0.40) | THRBTHRACYP2C9UGT1A1ABCG2 | |
| SCHEMBL29527933 | 0.82 | THRB (0.56) | THRBTHRACYP2C9UGT1A1ABCG2 | |
| SCHEMBL30558092 | 0.82 | THRB (0.47) | THRBTHRACYP2C9UGT1A1ABCG2 | |
| SCHEMBL24408055 | 0.82 | THRB (0.47) | THRBTHRACYP2C9UGT1A1ABCG2 | |
| SCHEMBL24407953 | 0.78 | THRB (0.53) | THRBTHRACYP2C9UGT1A1ABCG2 | |
| SCHEMBL24408058 | 0.75 | THRB (0.50) | THRBTHRACYP2C9UGT1A1ABCG2 | |
| SCHEMBL24408054 | 0.75 | THRB (0.51) | THRBTHRACYP2C9UGT1A1ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11786532-B2 | 2-pyridones and methods of use thereof | ALIGOS THERAPEUTICS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20220143032-A1 | 2-PYRIDONES AND METHODS OF USE THEREOF | ALIGOS THERAPEUTICS, INC. (US) | 2022-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220143032-A1 | 2-PYRIDONES AND METHODS OF USE THEREOF | PSEN2, MAPT, PNPO | THRB 1462/4885THRA 2147/4885CYP2C9 380/4885 |
| US-11786532-B2 | 2-pyridones and methods of use thereof | PSEN2, MAPT, PNPO | THRB 1462/4885THRA 2147/4885CYP2C9 380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.